Cognitive factors associated with adherence to oral antiestrogen therapy: Results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study

Cancer Prevention Research

Volumn 7, Issue 1, 2014, Pages 161-168

  Klepin, Heidi D ^a   Geiger, Ann M ^b   Bandos, Hanna ^c,d   Costantino, Joseph P ^c,d   Rapp, Stephen R ^a   Sink, Kaycee M ^a   Lawrence, Julia A ^a   Atkinson, Hal H ^a   Espeland, Mark A ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; RALOXIFENE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; COGNITION; COGNITIVE DEFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; SECONDARY ANALYSIS;

AGED; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; LOGISTIC MODELS; MEDICATION ADHERENCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; RALOXIFENE; RISK; TAMOXIFEN;

EID: 84892375634     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0165     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365: 1687-717.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-88.
3. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364: 2381-91.
4. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109: 832-9.
5. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19: 322-8.
6. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26: 549-55.
7. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21: 602-6.
8. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis- Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26: 556-62.
9. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009;27: 3445-51.
10. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006; 99: 215-20.
11. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99: 1763-8.
12. Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 2007;45: 431-9.
13. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011;125: 191-200.
14. Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 2006; 42: 2271-6.
15. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004;22: 3309-15.
16. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008;8: 155-61.
17. Stilley CS, Bender CM, Dunbar-Jacob J, Sereika S, Ryan CM. The impact of cognitive function on medication management: three studies. Health Psychol 2010;29: 50-5.
18. Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010;33: 219-27.
19. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, Lam M, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry 2009;17: 281-90.
20. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, LamMN, Mason KI, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology 2002;59: 1944-50.
21. Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the INRANGE study. Pharmacoepidemiol Drug Saf 2008;17: 853-60.
22. Solomon TM, Halkitis PN.Cognitive executive functioning in relation to HIV medication adherence among gay, bisexual, and other men who have sex with men. AIDS Behav 2008;12: 68-77.
23. Hayes TL, Larimer N, Adami A, Kaye JA. Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health 2009;21: 567-80.
24. Insel K, Morrow D, Brewer B, Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci 2006;61: 102-7.
25. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 2008;148: 427-34.
26. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27: 2758-65.
27. Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol 2009;27: 5144-52.
28. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727-41.
29. Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, et al. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) 2010; 19: 371-9.
30. Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on ageassociated cognitive decline. Clin Trials 2004;1: 440-50.
31. Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol 1991;4: 173-8.
32. Holtzer R, Verghese J, Wang C, Hall CB, Lipton RB. Within-person across-neuropsychological test variability and incident dementia. JAMA 2008;300: 823-30.
33. Adlam AL, Bozeat S, Arnold R, Watson P, Hodges JR. Semantic knowledge in mild cognitive impairment and mild Alzheimer's disease. Cortex 2006;42: 675-84.
34. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 2008;14: 266-78.
35. Tierney MC, Black SE, Szalai JP, Snow WG, Fisher RH, Nadon G, et al. Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. ArchNeurol 2001;58: 1654-9.